Natural History of Inhibitors in Severe Haemophilia A and B: Incidence and Prevalence

Inhibitors in Patients with Haemophilia

Volumn , Issue , 2008, Pages 3-8

  Lusher, J M ^a  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

Haemophilia a; Haemophilia b; Immune tolerance; Inhibitors; Risk factors

Indexed keywords

EID: 84949464061     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470757260.ch1     Document Type: Chapter

References (44)

1. Ehrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophilias. Lancet 1992; 339: 594-598.
2. Lusher JM, Arkin S, Abildgaard CF, Schwartz RD and the Kogenate Previously Untreated Patient Study Group. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. N Engl J Med 1993; 328: 453-459.
3. Bray GL, Gomperts ED, Courter S et al. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy and inhibitor risk in previously untreated patients with hemophilia A. Blood 1994; 83: 2428-2435.
4. Gruppo R, Bray GL, Schroth P, Perry M, Gomperts ED for the Recombinate PUP Study Group. Safety and immunogenicity of recombinant factor VIII (Recombinate) in previously untreated patients (PUPs): a 6.5 year update. Thromb Haemost 1997; 162 (June Suppl.): Abstract PD-663.
5. Lusher JM, Arkin S, Abildgaard CF, Hurst D and the Kogenate PUP Study Group. Recombinant FVIII (Kogenate) treatment of previously untreated patients (PUPs) with hemophilia A: update of safety, efficacy and inhibitor development after seven study years. Thromb Haemost 1997; 162 (June Suppl.): Abstract PD-664.
6. Rothschild C, Laurian Y, Satre EP et al. French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII: incidence of inhibitor and evaluation of immune tolerance. Thromb Haemost 1998; 80: 779-783.
7. Brown DL, Bray GL, Scharrer I. Transient inhibitors in patients with hemophilia A. Thromb Haemost 1999 (August Suppl.); 573:Abstract 1804.
8. Lusher JM, Gringeri A, Hann I, Rodriguez D. Safety, efficacy and inhibitor development in previously untreated patients (PUPs) treated exclusively with B-domain deleted recombinant FVIII (BDD rFVIII). Blood 1999; 94 (Suppl. 1): 23A (Abstract 1037).
9. Lusher JM, Kreuz W, Gazengel C et al. and the International Kogenate-FS PUP/MTP Study Group. Inhibitor formation monitoring in pediatric patients with severe hemophilia A receiving a second-generation rFVIII concentrate formulated with sucrose. Blood 1999; 94 (Suppl. 1): 237A (Abstract 1050).
10. Lusher JM. Etiology, natural history and management of FVIII inhibitors. Ann NY Acad Sci 1987; 509: 89-102.
11. Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients: a review of recent studies of recombinant and plasmaderived factor VIII concentrates. Haemophilia 1999; 5: 145-154.
12. Hay CRM. Review: why do inhibitors arise in patients with haemophilia A? Br Haematol 1999; 105: 584-590.
13. Kemball-Cook G, Tuddenham EGD. The factor VIII mutation database on the World Wide Web: the haemophilia A mutation, search, test and resource site HAMSTeRS update (version 3.0). Nucleic Acids Res 1997; 25: 128-132.
14. Tuddenham EGD, McVey JH. The genetic basis of inhibitor development in haemophilia A. Haemophilia 1998; 4: 543-545.
15. Schwaab R, Brackmann HH, Meyer C et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402-1406.
16. High KA. Factor IX: molecular structure, epitopes and mutations associated with inhibitor formation. In: Aledort LM, Hoyer LW, Lusher JM, Reisner HM, White GC, eds. Inhibitors to Coagulation Factors. New York: Plenum Press, 1995: 79-86.
17. Ljung RCR. Gene mutations and inhibitor formation in patients with hemophilia B. Acta Haematol 1995; 94 (Suppl. 1): 49-52.
18. Giannelli F, Green PM. The molecular basis of haemophilia A and B. Baillière's Best Prac Res Clin Haematol 1996; 9: 211-228.
19. Giannelli F, Green PM, Sommer SS et al. Haemophilia B (6th edn): a data base of point mutations and short additions and deletions. Nucleic Acids Res 1996: 24; 103-118.
20. Shapiro AD. Unique aspects of inhibitors in patients with hemophilia B. In: Shapiro A, ed. Inhibitors in Hemophilia: Current Perspectives and Future Directions. National Hemophilia Foundation: New York, 2001: 7-15.
21. White GCII. Predicting inhibitor development. In: Shapiro A, ed. Inhibitors in Hemophilia: Current Perspectives and Future Directions. National Hemophilia Foundation: New York, 2001: 43-52.
22. Astermark J, Berntorp E, White GC, Kroner BL and the MIBS Study Group. The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development. Haemophilia 2001; 7: 267-272.
23. Gill GM. The role of genetics in the development of factor VIII inhibitors. In: Shapiro A, ed. Inhibitors in Hemophilia: Current Perspectives and Future Directions. National Hemophilia Foundation:New York, 2001: 31-42.
24. Gill GM. The natural history of factor VIII inhibitors in patients with hemophilia A. Prog Clin Biol Res 1984; 150: 19-29.
25. Addiego JE, Kasper C, Abildgaard C et al. Increased frequency of inhibitors in African American hemophilia A patients. Blood 1994; 84 (Suppl. 1): 239 [Abstract].
26. Scandella D. Epitope specificity of anti-factor VIII antibodies. In:Shapiro A, ed. Inhibitors in Hemophilia: Current Perspectives and Future Directions. National Hemophilia Foundation: New York, 2001: 17-29.
27. White GC, DiMichele D, Mertens K et al. Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates: recommendation of the Scientific Subcommittee on factor VIII and factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1999; 81: 462.
28. Lusher JM, Shapiro A, Gruppo R, Bedrosian CL, Nguyen K and the ReFacto PUP Study Group. Safety and efficacy in previously untreated patients (PUPs) treated exclusively with B-domain deleted factor VIII (BDD rFVIII). Thromb Haemost 2001; Congress Suppl.: 2558 [Abstract].
29. Kreuz W, Manco-Johnson M, Gazengel C et al. Recombinant FVIII formulated with sucrose (rFVIII-FS) is safe and efficacious in pediatric patients with hemophilia A. Blood 2000; 96: 226A [Abstract].
30. Gringeri A, Kreuz W, Escuriola-Ettinghausen C et al. Anti-FVIII inhibitor incidence in previously untreated patients (PUPs) with hemophilia exposed to Kogenate (German-Italian PUP Study on Inhibitors). Thromb Haemost 1997; 648 (Congress Suppl. June):Abstract PS-2642.
31. Kasper CG, Aledort LM, Counts RB et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869-872.
32. Verbruggen B, Novakova I, Wessels H et al. The Nijmegen modification of the Bethesda assay for factor VIII inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-251.
33. Sandberg H, Almstedt A, Brandt J et al. Structural and functional characteristics of the B-domain deleted recombinant proteins, r-VIII SQ. Thromb Haemost 2001; 85: 93-100.
34. Berntorp E. Second generation, B-domain deleted recombinant factor VIII. Thromb Haemost 1996; 78: 256-260.
35. Lusher JM. Recombinant clotting factor concentrates. Baillière's Best Prac Res Clin Haematol 1996; 9: 291-303.
36. Kreuz W, Gazengel C, Gorina E, Kellermann E and the European PUP/MTP Study Group. Eighteen months experience with a sucrose-formulated full-length rFVIII (rVIII-SF) in previously untreated patients (PUPs) and minimally treated patients (MTPs) with severe hemophilia A. Ann Hematol 2001; 80: A37 [Abstract].
37. Lusher JM. Summary of clinical experience with recombinant factor VIII products: Kogenate. Ann Hematol 1994; 68: 53-56.
38. Sultan Y and the French Hemophilia Study Group. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. Thromb Haemost 1992; 67: 600-602.
39. Katz J. Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large-scale North American survey. Haemophilia 1996; 2: 28-31.
40. Soucie JM, Evatt B, Jackson D. Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators. Am J Hematol 1998; 59: 288-294.
41. Warrier I, Ewenstein BM, Koerper MA et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol 1997; 19: 23-27.
42. Thorland EC, Drost JB, Lusher JM et al. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia 1999; 5: 101-105.
43. Lusher JM. Inhibitor antibodies to factor VIII and factor IX: management. Semin Thromb Haemost 2000; 26: 179-188.
44. Lusher JM. Inhibitors in young boys with haemophilia. Baillière's Best Prac Res Clin Haematol 2000; 13: 457-468.